Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302807 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 931
- Enrollment target
NCT02302807: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT02302807 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 931 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02302807, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 931 participants
- Enrollment target
Study Summary
This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants.
Primary Outcome
OS was defined as time from randomization to death from any cause.
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Vinflunine
- DRUG Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 931 participants |
| Start Date | 2015-01-13 |
| Est. Completion | 2018-11-08 |
| Phase | Phase 3 |
What the finished NCT02302807 record still lists
NCT02302807 is an interventional study that assigns participants to a tested intervention. The registered 931 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (21% higher).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT02302807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02302807 about?
NCT02302807 is a clinical study titled "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]". This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or follow...
What is the current status of trial NCT02302807?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 931 participants. The study started on 2015-01-13. Estimated completion is 2018-11-08.
What interventions are being tested in trial NCT02302807?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Vinflunine (DRUG), Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody (DRUG).
Who is sponsoring clinical trial NCT02302807?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02302807's enrollment target sits among peer trials
931 338th of 2000 higher than 1,663 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- NCT06932029 · 930 participants · NA
SMBP Study: Improving High Blood Pressure in Older Adults With Multiple Chronic Diseases
- NCT07235085 · 930 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
- NCT04626635 · 933 participants · Phase 1
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI